HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Cholangiocarcinoma — Clinical Guidelines

Overview

Cholangiocarcinoma (CCA) is a malignancy arising from the biliary tree, categorized into intrahepatic, perihilar, and distal extrahepatic subtypes, each presenting unique challenges in diagnosis and management 1 3.

Diagnosis

Imaging: Utilize advanced imaging techniques including MRI, CT, and endoscopic ultrasound (EUS) for accurate staging 1 2.

Molecular Profiling: Incorporate genetic and molecular testing to refine classification and guide personalized treatment 1.

Endoscopic Techniques: Employ endoscopic retrograde cholangiopancreatography (ERCP) for both diagnostic and therapeutic interventions 9 17.

Pathology Reports: Ensure comprehensive pathology reports with detailed macroscopic and microscopic descriptions, ideally supported by clinical and imaging data 14.

Management

Surgical Resection: Curative treatment for early-stage disease; liver transplantation may be considered 1 12.

Neoadjuvant Therapy: Use neoadjuvant chemotherapy or chemoradiation to downstage tumors and improve surgical outcomes 2.

Locoregional Therapies: Employ interventional radiology techniques such as stenting, cryoablation, and photodynamic therapy (PDT) for palliation and local control 2 6 8 10.

Systemic Therapy: Consider targeted therapies like FGFR inhibitors (e.g., infigratinib) for advanced or metastatic disease 5.

Palliative Care: Focus on symptom management and quality of life, including endoscopic ablation techniques 9 17.

Special Populations

Comorbidities: Tailor management considering comorbidities; multidisciplinary care is crucial 2 7.

Elderly Patients: Evaluate fitness for surgery and consider less invasive treatments due to higher risk profiles 2.

Key Recommendations

Multidisciplinary Approach: Implement a multidisciplinary team for optimal management of perihilar CCA 2 (Evidence: Strong).

Molecular Characterization: Perform molecular profiling to guide personalized treatment strategies 1 (Evidence: Strong).

Use of Neoadjuvant Therapy: Consider neoadjuvant therapy to improve resectability and outcomes in resectable cases 2 (Evidence: Moderate).

Locoregional Therapies for Palliation: Utilize locoregional therapies including PDT and stenting for palliative care in unresectable cases 6 8 (Evidence: Moderate).

Targeted Therapy for Advanced Disease: Evaluate targeted agents like FGFR inhibitors for patients with advanced or metastatic CCA 5 (Evidence: Weak).

References

1 . EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma. Journal of hepatology 2025. link 2 Gaete MI, Meira Junior JD, Loyola S, Meneses L, Dreyse J, Hevia J et al.. OPTIMIZING PERIOPERATIVE CARE FOR PERIHILAR CHOLANGIOCARCINOMA: THE CRUCIAL ROLE OF MULTIDISCIPLINARY MANAGEMENT, NEOADJUVANT THERAPY, AND INTERVENTIONAL RADIOLOGY. Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery 2025. link 3 . EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. Journal of hepatology 2023. link 4 Rushbrook SM, Kendall TJ, Zen Y, Albazaz R, Manoharan P, Pereira SP et al.. British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma. Gut 2023. link 5 Zhao D, Long X, Zhou J, Wang J. Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System. Drugs in R&D 2023. link 6 Chen P, Yang T, Shi P, Shen J, Feng Q, Su J. Benefits and safety of photodynamic therapy in patients with hilar cholangiocarcinoma: A meta-analysis. Photodiagnosis and photodynamic therapy 2022. link 7 Cornman-Homonoff J, Bassik N, Madoff DC. Transhepatic portal stent placement and jejunal varix embolization for management of treatment-limiting gastrointestinal bleeding in a patient with unresectable recurrent intrahepatic cholangiocarcinoma. Clinical imaging 2020. link 8 Mosconi C, Calandri M, Javle M, Odisio BC. Interventional radiology approaches for intra-hepatic cholangiocarcinoma. Chinese clinical oncology 2020. link 9 Buerlein RCD, Wang AY. Endoscopic Retrograde Cholangiopancreatography-Guided Ablation for Cholangiocarcinoma. Gastrointestinal endoscopy clinics of North America 2019. link 10 Ierardi AM, Angileri SA, Patella F, Panella S, Lucchina N, Petre EN et al.. The role of interventional radiology in the treatment of intrahepatic cholangiocarcinoma. Medical oncology (Northwood, London, England) 2017. link 11 Karam D, Agrawal B, Mouli C. Digital lesion leading to diagnosis of cholangiocarcinoma. BMJ case reports 2017. link 12 Qureshi K, Jesudoss R, Al-Osaimi AM. The treatment of cholangiocarcinoma: a hepatologist's perspective. Current gastroenterology reports 2014. link 13 Prachayakul V, Chaisayan S, Aswakul P, Deesomsak M. Clinical characteristics and treatment outcomes of patients with unresectable cholangiocarcinoma in Thailand: are there differences dependent on stent type?. Asian Pacific journal of cancer prevention : APJCP 2013. link 14 Chatelain D, Farges O, Fuks D, Trouillet N, Pruvot FR, Regimbeau JM. Assessment of pathology reports on hilar cholangiocarcinoma: the results of a nationwide, multicenter survey performed by the AFC-HC-2009 study group. Journal of hepatology 2012. link 15 Masala S, Roselli M, Manenti G, Mammucari M, Bartolucci DA, Simonetti G. Percutaneous cryoablation and vertebroplasty: a case report. Cardiovascular and interventional radiology 2008. link 16 Zen Y, Aishima S, Ajioka Y, Haratake J, Kage M, Kondo F et al.. Proposal of histological criteria for intraepithelial atypical/proliferative biliary epithelial lesions of the bile duct in hepatolithiasis with respect to cholangiocarcinoma: preliminary report based on interobserver agreement. Pathology international 2005. link 17 Kubota Y, Takaoka M, Kin H, Ogura M, Yamamoto S, Tsuji K et al.. Endoscopic irradiation and parallel arrangement of Wallstents for hilar cholangiocarcinoma. Hepato-gastroenterology 1998. link 18 Patel BC, Hamilton P, Twomey J. A combined needle holder and scissors. Archives of ophthalmology (Chicago, Ill. : 1960) 1988. link

Cholangiocarcinoma